Description
Indication & Scope
Ivonescimab Injection is a first-line treatment for locally advanced or metastatic non-squamous non-small cell lung cancer.
- Mechanism: Bispecific antibody targeting PD-1 and VEGF. It blocks PD-1 immune checkpoint to activate anti-tumor T-cell immunity, while inhibiting VEGF-mediated tumor angiogenesis to suppress tumor growth and metastasis.
- Drug class: Bispecific monoclonal antibody, immunotherapy anti-neoplastic agent.
- Clinical use: First-line monotherapy or combination chemotherapy for unresectable locally advanced/metastatic non-squamous NSCLC without actionable driver gene mutations.
| Generic Name | Ivonescimab Injection |
| Brand Name | YiDaFang |
| Ingredient | Ivonescimab Injection |
| Dosage Form | Injection |
| Package | 100ml(10mg)*1 vial/box |
| Conditions Treated | Locally advanced or metastatic non-squamous non-small cell lung cancer |
| Taboos | 1. Severe hypersensitivity to ivonescimab or formulation excipients 2. Active autoimmune diseases or uncontrolled immune-related disorders 3. Active untreated interstitial lung disease 4. Pregnant and breastfeeding women |
| Place of origin | China |
| Prescription type | Prescription-only |
| Storage Conditions | Store unopened vials at 2°C to 8°C refrigeration, avoid freezing and direct sunlight. Do not shake the solution vigorously. |
| Manufacturer | KangFangSaiNuo Pharmaceutical, Ltd. |
| Registration Authority | National Medical Products Administration (NMPA), China |
| Approval number | S20240020 |
| Approval Date | May 21, 2024 |
| Shelf Life | 24 months |
How to use ?
Recommended Dose: 1800 mg intravenously once every 3 weeks. Dose delay or permanent discontinuation for grade 3+ immune-related adverse events.
Time: Intravenous infusion over 120 minutes on day 1 of each 21-day treatment cycle.
Instructions for use:
1. Premedication is not routinely required for first infusion.
2. Monitor patients closely for immune-related adverse events throughout treatment.
3. Hold treatment for severe immune toxicities and initiate corticosteroid rescue therapy if needed.
4. Do not mix with other infusion medications in the same IV line.
Interaction:
1. Systemic corticosteroids and immunosuppressants reduce anti-tumor efficacy.
2. Concurrent chemotherapy increases the risk of myelosuppression.
3. No direct CYP450 metabolic interactions with small-molecule drugs.
Side effects:
1. Common: Hypertension, fatigue, hypothyroidism, diarrhea, rash, infusion-related reactions.
2. Severe: Immune-related pneumonitis, colitis, hepatitis, myocarditis, severe hemorrhage from anti-VEGF activity.
Important Notice
This product should be administered only by qualified healthcare professionals in accordance with the approved prescribing information and local clinical guidelines. Dosage and administration may vary depending on patient condition, indicatiaon, and regional regulatory requirements.
Packaging & Shipping
Packaging
Original manufacturer’s packaging with secure export carton. Customized export packaging is available upon request.
Shipping Methods
Express Courier (EMS, DHL, FedEx, UPS), Air Freight, and Sea Freight. Cold-chain transportation is available for products requiring temperature-controlled logistics.
Export Support
Certificate of Analysis
GMP Certificate
Commercial Invoice
Packing List & CPP
Cold Chain Logistics
Customs Documentation
Scientific and regulatory sources
FAQ
What disease does Ivonescimab Injection treat?
It is used as first-line therapy for locally advanced or metastatic non-squamous non-small cell lung cancer.
What is Ivonescimab Injection's mechanism of action?
It is a bispecific antibody that blocks PD-1 immune checkpoint and inhibits VEGF-mediated angiogenesis.
What patients are contraindicated of Ivonescimab Injection?
Patients with active autoimmune diseases, untreated interstitial lung disease, or pregnant and breastfeeding women.
How long is the infusion time with Ivonescimab Injection?
Each infusion lasts 120 minutes on the first day of every 21-day cycle.
YiDaFang® | Ivonescimab Injection | Lung Cancer | DengYueRX
INN: Ivonescimab Injection
Indications: Lung Cancer
Dosage Form: Injection
Strength: 100ml(10mg)/vial
